FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1048-1050 March 13, 2003 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by O'Brien, S. G. PubMed Citation

Chronic myeloid leukemia (CML) is a clonal stem-cell disorder in which the reciprocal translocation t(9;22) generates two novel fusion genes: BCR-ABL on the derivative 22q– (Philadelphia) chromosome, and ABL-BCR on chromosome 9q+. The ABL gene product is a protein tyrosine kinase, and the fusion protein BCR-ABL has constitutive kinase activity that deregulates signal transduction pathways, causing abnormal cell cycling, inhibition of apoptosis, and increased proliferation of cells. The natural course of the disease is usually characterized by three sequential phases (the chronic, accelerated, and blast-crisis phases), during which there is progressively more resistance to therapy.

Interferon alfa therapy extends survival . . . [Full Text of this Article]

Source Information

From the Royal Free and University College London Medical School, London.

This article has been cited by other articles:

• Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., Hughes, T. (2007). BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Clin. Cancer Res. 13: 7080-7085 [Abstract] [Full Text]  
• Zhou, G.-B., Kang, H., Wang, L., Gao, L., Liu, P., Xie, J., Zhang, F.-X., Weng, X.-Q., Shen, Z.-X., Chen, J., Gu, L.-J., Yan, M., Zhang, D.-E., Chen, S.-J., Wang, Z.-Y., Chen, Z. (2007). Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109: 3441-3450 [Abstract] [Full Text]  
• Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., Cortes, J. (2006). New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. ANN INTERN MED 145: 913-923 [Abstract] [Full Text]  
• Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R., Hehlmann, R. (2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809-1820 [Abstract] [Full Text]  
• Kim, H. J., Jung, C. W., Kim, K., Ahn, J. S., Kim, W. S., Park, K., Ko, Y. H., Kang, W. K., Park, K. (2006). Isolated Blast Crisis in CNS in a Patient With Chronic Myelogenous Leukemia Maintaining Major Cytogenetic Response After Imatinib. JCO 24: 4028-4029 [Full Text]  
• Ferrari-Amorotti, G., Keeshan, K., Zattoni, M., Guerzoni, C., Iotti, G., Cattelani, S., Donato, N. J., Calabretta, B. (2006). Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP{alpha}. Blood 108: 1353-1362 [Abstract] [Full Text]  
• Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schoffski, P., Van Oosterom, A., Marynen, P., Debiec-Rychter, M. (2006). Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate. Clin. Cancer Res. 12: 2622-2627 [Abstract] [Full Text]  
• Mauro, M. J., Maziarz, R. T. (2006). Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?. Mayo Clin Proc. 81: 404-416 [Abstract] [Full Text]  
• Stem Cell Trialists' Collaborative Group, (2005). Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials. JCO 23: 5074-5087 [Abstract] [Full Text]  
• O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W.N., Druker, B. J. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Res. 65: 4500-4505 [Abstract] [Full Text]  
• Garipidou, V., Vakalopoulou, S., Tziomalos, K. (2005). Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate. The Oncologist 10: 457-458 [Full Text]  
• Yin, T., Wu, Y.-L., Sun, H.-P., Sun, G.-L., Du, Y.-Z., Wang, K.-K., Zhang, J., Chen, G.-Q., Chen, S.-J., Chen, Z. (2004). Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104: 4219-4225 [Abstract] [Full Text]  
• O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A. III, Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Shakespeare, W. C., Dalgarno, D., Clackson, T., Sawyer, T. K., Deininger, M. W., Druker, B. J. (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104: 2532-2539 [Abstract] [Full Text]  
• Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G., Serkova, N. J. (2004). Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells. Clin. Cancer Res. 10: 6661-6668 [Abstract] [Full Text]  
• Stone, R. M. (2004). Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach. The Oncologist 9: 259-270 [Abstract] [Full Text]  
• Guilhot, F. (2004). Indications for Imatinib Mesylate Therapy and Clinical Management. The Oncologist 9: 271-281 [Abstract] [Full Text]  
• Peng, B., Dutreix, C., Mehring, G., Hayes, M. J., Ben-Am, M., Seiberling, M., Pokorny, R., Capdeville, R., Lloyd, P. (2004). Absolute Bioavailability of Imatinib (Glivec(R)) Orally versus Intravenous Infusion. J Clin Pharmacol 44: 158-162 [Abstract] [Full Text]  
• Bartolovic, K., Balabanov, S., Hartmann, U., Komor, M., Boehmler, A. M., Buhring, H.-J., Mohle, R., Hoelzer, D., Kanz, L., Hofmann, W.-K., Brummendorf, T. H. (2004). Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103: 523-529 [Abstract] [Full Text]  
• McKelvey, K. D. Jr., Evans, J. P. (2003). Cancer Genetics in Primary Care. J. Nutr. 133: 3767S-3772 [Abstract] [Full Text]  
• Kelloff, G. J., O'Shaughnessy, J. A., Gordon, G. B., Hawk, E. T., Sigman, C. C. (2003). Counterpoint: Because Some Surrogate End Point Biomarkers Measure the Neoplastic Process They Will Have High Utility in the Development of Cancer Chemopreventive Agents against Sporadic Cancers. Cancer Epidemiol. Biomarkers Prev. 12: 593-596 [Full Text]  
• (2003). New Gold Standard for Treatment of CML. JWatch General 2003: 3-3 [Full Text]  
• Melo, J. V., Hughes, T. P., Apperley, J. F. (2003). Chronic Myeloid Leukemia. ASH Education Book 2003: 132-152 [Abstract] [Full Text]